The DHE nasal spray delivered pain relief at 2 hours for 66% of patients; 93% of those remained pain-free at 24 hours and 86% at 2 days post-dose.
Oral CGRP inhibitor atogepant significantly reduced monthly headache days and improved daily function in adults with 4 to 14 headaches per month.
A woman in her 50s who has a history of tension headache presents to the ED with a headache different from any she has had. Mild photophobia is the only finding on physical exam. Your dx?
Study: Anosmia, myalgias, and headache were the most common extrapulmonary symptoms seen in COVID-19 patients at first presentation, say investigators.
A recent survey queried cluster headache patients to compare cluster headache pain intensity to other painful disorders. The results, highlighted in this quick slideshow, may surprise.
In animal models, pain relief from cannabis has been found to be greater in females; new research on pain relief from inhaled cannabis in regular users found something different.
Incident cardiovascular disease is significantly increased among women with migraine with aura vs migraineurs without aura and those who do not have migraine.
Analysis of data from more than 21 000 migraineurs found that less than 1 in 3 take prescribed acute medications and less than 1 in 5 take prescribed preventive agents.
Injectable medications for migraine are effective, inexpensive, and easy to store. Try these 5 questions on 5 you may want to have on hand.
Migraine-especially with aura-is a CV risk factor, which makes treatment with ergots or triptans potentially problematic. The best approach?